Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
As well as discovering new therapeutic targets, we also have the ability to continue the drug discovery process by following up with our commercial service offers, in particular DRIVE-IDDS (Small Molecule; Molecular RadioTherapy).
This support will also be provided along with our partners at the FederAIdd Campus and will speed up the process by deploying AI technology at each stage. The AI BU will liaise with our partners and remain your single point of contact up to the clinical phases.